Gilead JAKs up oncology presence with $510m YM buy
This article was originally published in Scrip
YM BioSciences surged 76.7% to close at $2.88 per share on 12 December after Gilead Sciences said it would pay $2.95 per share to buy YM and expand its oncology pipeline, valuing the Canadian developer of the selective janus kinase (JAK) 1 and 2 inhibitor CYT387 at US$510 million.
You may also be interested in...
Private investors, including Japanese e-commerce mogul Hiroshi Mikitani, backed a $150m Series C round for Rakuten Aspyrian and its photoimmunotherapy platform. Also, pharma-backed therapeutic video game developer Akili boosts Series C to $68m, and Summit garners additional BARDA funding.
The JAK inhibitor momelotinib meets some endpoints but misses others in two late-stage clinical studies in myelofibrosis, a condition that has proved recalcitrant to various new approaches, leaving Incyte/Novartis’s marketed product ruxolitinib as one of the few successes.
Private Company Edition: Patient Square’s private equity fund, which surpassed its $3bn fundraising goal, may invest broadly across health care but the firm already has invested heavily in biopharma. Also, investor Dimension launches with a $350m specialized VC fund and Alto increased its series B to $60m.